Barron takes on business development role
Eurofins AvTech Laboratories has appointed Michael Barron as director of business development.
Barron has previously worked for Catalent Pharma Solutions, Cardinal Health, and other leading contract drug development and analytical service companies.
AvTech offers analytical support for all stages of drug discovery and development from early ADME studies of drug candidates to stability and release testing of the finished product. The company places particular emphasis on the development, validation, and routine performance of GMP and GLP compliant methods.
You may also like
Regulatory
![Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS]()
Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS
The clearance enables a first-in-human trial of the UCB-licensed remyelination candidate, marking the first GPR17 programme to reach clinical development for multiple sclerosis and related demyelinating diseases
Research & Development
![Promega UK Launches Lumit Cell Proliferation Assay (Human Ki-67) for rapid, wash-free detection of a key proliferation marker]()
Promega UK Launches Lumit Cell Proliferation Assay (Human Ki-67) for rapid, wash-free detection of a key proliferation marker
New homogeneous, plate-based assay enables researchers to track hKi-67 in a simple add-and-read format, delivering robust and reproducible results in less time
Research & Development
![BioArctic and Lilly sign $30m collaboration combining BrainTransporter with Lilly neurodegeneration asset]()
BioArctic and Lilly sign $30m collaboration combining BrainTransporter with Lilly neurodegeneration asset
The deal, worth up to $800m including milestones, marks BioArctic's fourth BrainTransporter partnership — joining existing collaborations with Eisai, Bristol Myers Squibb and Novartis to advance brain-targeted biologics delivery
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
![Mabion and Oddifact to explore orphan drug potential of MabionCD20 through new collaboration]()
Mabion and Oddifact to explore orphan drug potential of MabionCD20 through new collaboration
Mabion has signed a letter of intent with Oddifact to reposition its Phase III-stage CD20 monoclonal antibody candidate for rare disease indications, leveraging AI-driven orphan drug identification and existing manufacturing expertise
